- Home
- BNTX
BNTX
BioNTech SE
as of 09-15-2026 3:46pm EST
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
| Founded: | 2008 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 24.7B | IPO Year: | 2019 |
| Target Price: | $133.46 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $79.81 - $124.00 | Next Earning Date: | 05-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -20.35% | Revenue Growth (next year): | 3.37% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered BNTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of BioNTech SE (BNTX)
Chief Executive Officer
Avg Cost/Share
$99.45
Shares
41,000
Total Value
$4,077,314.70
Owned After
602,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$96.93
Shares
45,000
Total Value
$4,362,021.00
Owned After
602,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$96.31
Shares
20,500
Total Value
$1,974,287.35
Owned After
602,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$97.78
Shares
36,000
Total Value
$3,520,144.80
Owned After
602,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$99.20
Shares
37,000
Total Value
$3,670,518.40
Owned After
602,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$103.52
Shares
31,500
Total Value
$3,260,823.30
Owned After
602,209
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$102.85
Shares
45,000
Total Value
$4,628,232.00
Owned After
602,209
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 14, 2026 | Sell | $99.45 | 41,000 | $4,077,314.70 | 602,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 11, 2026 | Sell | $96.93 | 45,000 | $4,362,021.00 | 602,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 10, 2026 | Sell | $96.31 | 20,500 | $1,974,287.35 | 602,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 9, 2026 | Sell | $97.78 | 36,000 | $3,520,144.80 | 602,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 8, 2026 | Sell | $99.20 | 37,000 | $3,670,518.40 | 602,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 4, 2026 | Sell | $103.52 | 31,500 | $3,260,823.30 | 602,209 | |
| Sahin Ugur | BNTX | Chief Executive Officer | Sep 3, 2026 | Sell | $102.85 | 45,000 | $4,628,232.00 | 602,209 |
Compare BNTX vs Leading Stocks
See how BNTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BNTX BioNTech SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.